SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

October 26, 2015 12:40 ET

CTD Holdings Names Dr. Rita Colwell and Dr. Sharon Hrynkow Co-Chairs of Scientific Advisory Board

ALACHUA, FL--(Marketwired - October 26, 2015) - CTD Holdings, Inc. (OTCQB: CTDH) today announced Dr. Rita Colwell, Distinguished University Professor, University of Maryland at College Park and Johns Hopkins University Bloomberg School of Public Health, has joined their Scientific Advisory Board (SAB) and will co-chair the SAB with Dr. Sharon Hrynkow, Senior Vice President for Medical Affairs, CTD.

"As CTD develops its platform for cyclodextrin-based drugs, Dr. Colwell and Dr. Hrynkow will provide valuable insights and leadership in identifying promising directions leading to effective treatments," said N. Scott Fine, CTD Chairman and CEO. "I am confident their vision and experience will benefit patients, especially those with Niemann-Pick Type C."

Niemann-Pick Type C (NPC) is a rare and usually fatal cholesterol metabolism disease seen primarily in children and with an adult-onset form.

Dr. Colwell's research on understanding cholera and how the environment serves as a reservoir of the causative agent of cholera has led to life-saving practices and therapies that have benefited millions living in cholera-endemic areas. Dr. Colwell served as Director of the National Science Foundation from 1998 to 2004. She is a member of the National Academy of Sciences and has authored 17 books and more than 750 scientific publications. Dr. Colwell is founder of CosmosID, a Maryland-based bioinformatics company with technology that allows rapid detection and identification of bacteria, viruses, fungi and parasites in clinical and environmental samples. Her many honors include the 2006 National Medal of Science and the 2010 Stockholm Water Prize.

"CTD offers the potential for highly significant contributions to treatments for NPC and other diseases," said Dr. Colwell. "I look forward to working with CTD to explore new ways to employ cyclodextrins in the treatment of a range of diseases."

Dr. Hrynkow leads the clinical program at CTD, which includes gaining market approval of Trappsol®Cyclo™ for treatment of NPC. A developmental neurobiologist by training, Dr. Hrynkow spent 20 years in public service at the National Institutes of Health and State Department, working to advance the health of people globally. Dr. Hrynkow is the recipient of the U.S. President's Rank Award for Meritorious Senior Executive, the Order of Merit awarded by the King of Norway, and is an elected member of the Council on Foreign Relations and Fellow of the American Association for the Advancement of Science.

"I have had the great privilege of collaborating with Dr. Colwell on programs and policy initiatives prior to my work at CTD," said Dr. Hrynkow. "I look forward to working with her in this new endeavor to identify novel research approaches to treat NPC and other diseases that respond to cyclodextrins."

Caroline Hastings, M.D., Pediatric Oncologist, UCSF Benioff Children's Hospital, Oakland, California; Benny Liu, M.D, Gastroenterologist, Alameda County Medical Center, Highland General Hospital, California; and James Hildreth, M.D., Ph.D., President and CEO, Meharry Medical College, Tennessee, are current members of the CTD Scientific Advisory Board.

About the Company:
CTD Holdings, Inc. is a biotechnology company developing cyclodextrin-based products for the treatment of disease, including Trappsol® Cyclo™, an orphan drug designated product, for treatment of Niemann-Pick Type C, a rare and serious genetic disease in young children which also results in significant health impairment for affected adults. Additional indications for the active ingredient in Trappsol® Cyclo™, including peripheral artery disease, diabetic nephropathy, and acute viral infections, are also in development.

The company's other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics and nutrition markets. They also operate the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes and supply cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the Company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information